Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENEGENE-1 lead-in prophylaxis study in adult hemophilia B and hemophilia A
2017-001271-23Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of coagulation factor ix and Factor VIII in hemophilia B (HB) and hemophilia A (2 arms), sponsored by Pfizer. Primary endpoints: Prospective efficacy of prophylaxis replacement therapy and Selected safety events during prophylaxis replacement therapy. Started Aug 2018; status: completed.
02
Drugs
coagulation factor ixFactor VIII
03
Conditions
hemophilia B (HB)hemophilia A
Beyond the preview
Go deeper on 2017-001271-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001271-23.